Tag: biotechnology
-
$2 Billion Biotech Licensing Deal Cancelled
A licensing deal with a potential value of more than $2 billion between two biotechnology companies for a new breast cancer drug was cancelled on Friday.
-
Growing Engineered Algae Outdoors Shown Feasible, Safe
A test of cultivating genetically engineered algae in outdoor tanks shows the production technique is feasible and does not pose risks to native algae populations.
-
Gene Therapy Start-Up Raises $41M in Early Funds
A 1 year-old enterprise developing gene therapies to treat rare inherited metabolic disorders is raising €37.5 million ($US 40.8 million) in its first venture funding round.
-
Stem Cell Parkinson’s Model Devised for Drug Screening
A team from University at Buffalo created brain cells from adult stem cells that in lab tests display the same nerve misfirings seen in people with Parkinson’s disease.
-
Crispr, Stem Cells Produce Precise Arthritis Therapy
Editing the genes in stem cells is shown to produce cartilage that in lab tests releases therapeutic proteins only when needed to relieve joint inflammation in arthritis.
-
Smartphone-Controlled Cells Produce Insulin on Demand
A system designed by researchers in China and Switzerland and controlled by a smartphone app was shown in lab mice to produce insulin on demand from engineered pancreas cells.
-
Vaccine R&D Underway to Protect Against Animal Microbes
Research is underway in the U.K. on development of new vaccines to protect humans against zoonotic diseases, infectious diseases originating in animals.
-
Nanoparticles Boost T-Cells to Fight Leukemia
A cancer research lab designed a process to treat leukemia by reprogramming cells in the immune system with genes on nanoscale biodegradable particles.
-
Crispr-Based Diagnostics System Designed
A bioengineering team from Harvard University and Massachusetts Institute of Technology designed simple, inexpensive diagnostics tools to detect infectious diseases, based on Crispr, an emerging genome-editing technology.
-
Cancer Gene Therapy Company Raises $85M in IPO
A developer of cancer immunotherapies that transfer gene treatments into patients with brain tumors is raising $85 million in its initial public stock offering.